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The calcineurin inhibitor Tacrolimus 
specifically suppresses human  
T Follicular helper cells
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Background: T follicular helper (Tfh) cells are key players in the production of anti-
body-producing B  cells via the germinal center reaction. Therapeutic strategies tar-
geting Tfh cells are important where antibody formation is implicated in disease, such 
as transplant rejection and autoimmune diseases. We investigated the impact of the 
immunosuppressive agent tacrolimus on human Tfh cell differentiation and function in 
transplant recipients.
Methods: Paired blood and lymph node (LN) samples were obtained from 61 transplant 
recipients immediately prior to organ implantation. Living-donor recipients received a 
week of tacrolimus prior to kidney transplantation. Deceased-donor recipients served 
as controls, as tacrolimus was not administered until after the transplant operation. Flow 
cytometry was used to compare LN and circulating cell subsets.
results: The calcineurin inhibitor (CNIs) tacrolimus specifically suppresses both LN Tfh 
cells and circulating Tfh cells, but not their regulatory counterparts or other CD4 T cell 
subsets.
conclusion: Our findings suggest that CNIs may have a more important role in the pre-
vention of antibody formation than previously understood and, therefore, have potential 
for antibody-associated conditions in which aberrant Tfh function has been implicated 
in disease.
Keywords: T follicular helper cells, T follicular regulatory cells, immunosuppression, transplantation immunology, 
germinal centers
inTrODUcTiOn
The germinal center (GC) reaction is required to form long-lasting antibody responses and requires 
interactions between many different cell types; GC B  cells, T follicular helper (Tfh) cells, and T 
follicular regulatory (Tfr) cells (1, 2). By acting in concert, these cells support the development 
of memory B cells that can respond quickly to future infections, and long-lived plasma cells that 
migrate to the bone marrow and secrete high affinity, class-switched antibodies. The long-lived 
humoral immunity produced from the GC is the cornerstone of successful vaccination, but can result 
in negative health outcomes when the response is directed to self-antigens, or alloantigens in the 
context of transplantation (3). Therefore, therapeutic strategies to manipulate the GC response are 
required in diseases where there is an unmet clinical need to suppress aberrant humoral immunity, 
for example, in autoimmune disease or transplant rejection.
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Investigating the differentiation and function of the cells 
involved in the GC response and the effect of therapeutic agents 
is, therefore, important but challenging, due to the scarcity of 
fresh human secondary lymphoid tissue. Transplant recipients 
offer a unique opportunity to analyze paired blood and lymph 
node (LN) samples, enabling direct comparison of circulating 
and tissue resident populations (4) and the effects of immunosup-
pressive therapy, as reported here.
This clinical setting is also ideal for determining the effect 
of immunosuppressive therapy on Tfh cells, and their circulat-
ing counterparts. Calcineurin inhibitors (CNIs) are widely 
used in transplantation, a key mechanism of their action is 
blockade of NFAT signaling, which is known to be important 
for Tfh development and differentiation in mice (5). We have 
taken advantage of the unique opportunity to obtain paired 
blood and LN samples from the same individual undergoing 
a transplant to compare the effects of the CNI tacrolimus on 
both LN and circulating Tfh (cTfh) and Tfr cells. Living-donor 
kidney transplant recipients at the Oxford Transplant Centre 
receive 1 week of tacrolimus monotherapy prior to the planned 
operation. In contrast, deceased-donor transplant recipients 
receive tacrolimus only after the operation but are otherwise 
equivalent in having chronic kidney disease stage 5, with its 
associated generalized immunosuppressive effect (6). We 
obtained paired blood and LN samples from both groups of 
patients immediately prior to the operation, allowing compari-
son of the effects of the CNI tacrolimus on both blood and LN 
T and B cells.
Because, in humans, access to lymphoid tissue-resident Tfh 
cells is challenging, most studies have used a circulating bio-
marker of these cells. Circulating counterparts of Tfh and Tfr 
cells, described in mice and in humans, share the same surface 
markers as GC cells and are thought to be memory cells, capable 
of rapid initiation of antibody responses upon re-encounter with 
antigen (7–11). Our paired blood and tissue sampling protocol 
enables direct comparison of LN Tfh and their circulating coun-
terparts. cTfh cells express the chemokine receptor CXCR5, and 
can be further subdivided into subsets using cytokine receptors 
that are hallmarks of other helper T  cell subsets. cTfh1 cells 
express CXCR3, and IFNγ. Similarly, cTfh17 cells express CCR6 
and secrete IL-17. cTfh2 cells do not express either CXCR3 or 
CCR6 but can secrete IL-4. These cells have different capacity for 
B cell help; cTfh2 and cTfh17 are capable of helping both naïve 
and memory B cells produce antibody in vitro; while cTfh1 cells 
provide help to memory B cells, but not naïve cells. Furthermore, 
the helper capacity of cTfh1 cells appears to be restricted to those 
expressing high levels of ICOS and PD-1 (7, 10).
An increased frequency of cTfh cells has been identified in 
a myriad of human autoimmune diseases; including systemic 
lupus erythematosus, rheumatoid arthritis, and autoimmune 
thyroid disease, and appears to correlate with autoantibody 
level and/or disease severity (12–18). Similar increases in blood 
CXCR3+CXCR5+ICOS+ Tfh cells occurred 7 days after influenza 
vaccination and correlated with anti-influenza antibody and plas-
mablast production (10). An increased proportion of circulating 
CXCR3−CXCR5+PD-1+ Tfh cells is also seen in those patients 
with HIV infection who go on to form broadly neutralizing 
antibodies (9). Taken together, this research indicates that cTfh 
cells can be a circulating biomarker of GC activity in both health 
and disease. Because of their role in antibody development and 
the clinical problem of de novo donor-specific antibodies (DSAs) 
in transplantation, one study identified that patients with pre-
formed DSA had increased numbers of circulating CXCR5+CD4+ 
cells after transplantation compared to those without, but found 
no differences in patients developing de novo DSA (19). More 
recently, increased numbers of CXCR5+CD4+ cells with low PD-1 
expression have been described in a small cohort of patients with 
chronic rejection, compared to those with stable renal function. 
However the group was heterogeneous with varied immunosup-
pressive regimens (20). In liver transplantation, no change was 
seen in the number of CXCR5+CD4+ cells after transplantation, 
but their effector function through IL-21 production was reduced 
(21), consistent with in vitro work showing that blockade of IL-21 
can prevent alloreactive B  cell differentiation (22). Despite the 
interest in Tfh and Tfr cells in transplantation, little is currently 
known about how currently used immunosuppressive agents 
impact the development or function of these cells (23). An in vitro 
model suggested that CNIs may suppress Tfh cell development 
(24); however, so far, there is little evidence in vivo, and it is not 
clear if these effects are specific to Tfh cells or shared with other 
T cell subsets.
Here, we report that a week of tacrolimus treatment reduces 
cTfh cells in the periphery and Tfh precursor cells in the LN 
without a significant impact on other CD4 T cell subsets. This is 
supported by in vitro work demonstrating that addition of tac-
rolimus to a Tfh-B cell co-culture prevents B cell maturation and 
antibody production. These data suggest that tacrolimus could be 
an effective clinical intervention for targeting Tfh cells in humans.
PaTienTs anD MeThODs
Patients
This study was conducted in compliance with Good Clinical 
Practice and the Declaration of Helsinki, and received ethical 
approval from the Local Research Ethics Committee, REC refer-
ence 14/SC/0091. Written informed consent was obtained from 
all patients.
Kidney and simultaneous pancreas-kidney (SPK) transplant 
recipients were recruited over an 8-month period from May to 
December 2014 from the Oxford Transplant Centre. Patients 
with known pre-formed donor-specific anti-HLA antibodies 
and those undergoing planned pre-transplant desensitization 
with antibody removal were excluded, but those with a negative 
pre-transplant cross-match to donor HLA were approached for 
study-specific consent. Details of patients are shown in Table 1. 
In total, 42 kidney alone and 19 SPK recipients were recruited 
to the study and provided paired blood and tissue samples. SPK 
recipients had a median age of 47 (range 30–59) and were evenly 
sex-matched (9 male, 10 female). Kidney recipients had a median 
age of 54 (range 26–74) and had a male preponderance (31 male, 
11 female). 16 of 42 kidney-alone samples were from live-donor 
recipients; the remaining 26 kidney-alone and all 19 SPK samples 
were from deceased donor recipients.
TaBle 1 | Table of patient characteristics at recruitment.
Kidney Kidney pancreas
Number recruited 42 19
Sex male/female 31M/11F 9M/10F
Median age (range) 54 (26–74) 47 (30–59)
Donor type
Living (male/female) 16 (11M/5F) n/a
DBD (male/female) 11 (7M/4F) 16 (7M/9F)
DCD (male/female) 15 (13M/ F) 3 (2M/1F)
Drug treatment regimen
Alemtuzumab 19 19
Basiliximab + MMF 13 n/a
Basiliximab + Aza 10 n/a
61 patients were recruited in total.
DBD, donor after brainstem death; DCD, donor after cardiac death; MMF, 
mycophenolate mofetil; Aza, azathioprine.
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All patients received a dose of an antimetabolite (azathio-
prine or MMF) 2 h prior to transplantation. Patients receiving 
kidneys from live-donors also received 1  week of treatment 
with tacrolimus (aiming for trough levels of 5–15 ng/L) prior to 
transplantation. Only those patients with no evidence of acute 
infection at the time of admission went ahead to receive the 
transplant.
At the time of transplant, 50 ml of blood was taken immediately 
after induction of anesthesia, and lymphoid tissue was removed 
prior to organ implantation, to allow access to blood vessels as 
part of the routine operative procedure. LN from kidney recipi-
ents were from the inguinal region; those from SPK recipients 
were from the para-aortic region.
Data from an independent cohort of patients with end-stage 
renal failure undergoing kidney transplantation at another 
transplant center are included in Figure  3. These patients also 
provided written informed consent to use of their samples for 
research, and the samples were collected and processed in the 
same manner as in this study (4).
sample Preparation
Blood samples were prepared over a density gradient as previously 
described and LN samples made into a single cell suspension as 
previously described (4). Samples were cryopreserved in a mix of 
90% fetal calf serum and 10% DMSO, then thawed and stained 
for flow cytometry in batches to reduce any variation between 
individual samples that would be introduced from processing. 
Defrosted samples were washed, counted, and 3 × 106 cells added 
to each polypropylene tube for flow cytometry.
All samples were incubated with human Fc block (eBioscience) 
to prevent non-specific antibody binding. A cocktail of surface 
antibodies was added and samples incubated for 30 min at room 
temperature. They were washed; streptavidin and live/dead stains 
were added for a further 10 min at room temperature, samples 
were then washed again, and fixed using eBioscience Foxp3 
staining fixation/permeabilization buffer for 45 min at 4°C as per 
manufacturers protocol. Antibodies to intracellular proteins were 
added and samples incubated for 60 min at 4°C. Samples were 
run on a BD LSR Fortessa cell analyzer. Antibody cocktails were 
mixed in brilliant violet stain buffer (BD biosciences) to prevent 
“budding” of the negative population, as recommended by BD 
bioscience.
antibodies
Anti-human CD38 (clone HIT2), CD19 (clone SJ25C1), HLA-DR 
(clone G46-6), CD45RA (clone HI100), CXCR5 biotin (clone 
RF8B2), PD-1 (clone EH12.1), IL-7R (clone HIL-7R-M21), Bcl6 
(clone K112-91), IgM (clone H1-FB1), CXCR3 (clone IC6), CD57 
(clone NK-1), PD-1 (clone EH12.1) CXCR3 (clone 1C6/CXCR3), 
and CD27 (clone M-T271), all BD Biosciences. Anti-human IgD 
(clone IA6-2), CCR7 (clone 3D12), CCR6 (clone R6H1), CD27 
(clone O323) and CD4 (clone OKT4), all eBioscience. Anti-
human CD24 (clone ML5), ICOS (clone C398.4A), Foxp3 (clone 
259D), CD25 (clone M-A251), streptavidin brilliant violet 605, 
CD4 (clone OKT4), CXCR5 (clone J252D4), CD3 (clone OKT3), 
CD19 (clone HIB19), and DAPI, all BioLegend. Invitrogen near-
IR fixable live-dead stain kit.
Tfh and B-cell co-cultures
Cells for in vitro co-cultures were obtained from leukocyte cones 
from platelet donors attending the Oxford Blood Donation Centre 
at the John Radcliffe hospital. Original consent to use of samples 
was provided to NHS Blood and Transplant, and samples made 
available for research under local HTA licensing. Isolated PBMCs 
were pre-enriched for B  cells (CD19 Dynabead/Detatchabead 
kit, Invitrogen) and CD4+ T cells (Miltenyi CD4 negative isola-
tion kit). CD19+CD27+ memory B  cells and CXCR5+CXCR3+ 
Tfh1, CXCR5+CXCR3− Tfh2/17 or CXCR5−CXCR3+/− Teffector 
cells were flow-sorted from pre-enriched populations and then 
cultured in 96-well U-bottom tissue culture plates (3 ×  104 of 
each cell type per well) in the presence of 1 µg/ml staphylococcal 
enterotoxin B (SEB, Sigma). After 11 days of co-culture, superna-
tants were retrieved for ELISA and replicate wells combined for 
flow cytometry of cells.
For drug cultures, tacrolimus (Sigma F4679) solubilized in 
DMSO was used at 8  ng/ml. This is the mid-range of recom-
mended dosing for patients (5–15 ng/ml) (25, 26) and in keeping 
with previous in vitro work (27). Control samples were run with 
DMSO vehicle alone.
igg and igM elisa
Secretion of IgM and IgG was determined by ELISA using the 
eBioscience Ready-Set-Go! ELISA kits for human total IgG 
(eBioscience) and human IgM (eBioscience), using polystyrene 
high-binding 96-well plates, according to eBioscience recom-
mended protocol.
statistical analysis
Statistical analysis was performed using Graph Pad Prism soft-
ware. Patient samples were analyzed with the Mann–Whitney 
test. Co-culture samples were analyzed with one-way ANOVA 
comparing treated to untreated samples with either Bonferroni 
or Dunnett’s multiple comparison test. Absolute cell counts for 
peripheral blood samples were calculated using the proportion 
of lymphocytes for each subset multiplied by hospital laboratory 
lymphocyte counts taken at the same time as the original sample.
FigUre 1 | Tacrolimus treatment reduces circulating Tfh frequency. Samples were gated on lymphocytes then live CD4+ cells. (a) T follicular helper (Tfh) were 
identified as CXCR5+PD-1+CD4+, with activated Tfh (B) identified as CXCR5+PD-1++CD4+. CXCR5+PD-1+CD4+ Tfh shown as proportion (c) and absolute count  
(D) in live donor recipients who had received a week of tacrolimus (tacrolimus-treated, n = 16) compared to untreated deceased donor recipients (untreated, 
n = 45). CXCR5+PD-1++CD4+ activated Tfh shown as proportion (e) and absolute count (F). (g) CD4+CXCR5+ cells were subdivided into CXCR3+CCR6− Tfh1, 
CXCR3−CCR6− Tfh2 and CXCR3−CCR6+ Tfh17 and are shown as both proportion of CD4+cells (h) and absolute cell count (i) in tacrolimus-treated patients 
compared to untreated. There were no reductions in any other CD4 T cell subset, CXCR3+CXCR5−CD45RA− Th1 cells are shown as an example with (J) proportion 
of CD4+ and (K) absolute cell count. Shown as median and interquartile range, each symbol represents one patient. Samples compared with Mann–Whitney test, 
only significant differences are shown on graphs.
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resUlTs
Pre-Transplant Tacrolimus Treatment 
significantly reduces cTfh cell number
Patients were recruited into the study at the time of transplant; 
and were, therefore, all either receiving or within 6  months of 
requiring renal replacement therapy. Those who had received a 
transplant from a living-donor (n = 16) had been treated with 
the CNI tacrolimus for 1 week prior to transplantation, aiming 
for trough levels of 5–10  ng/ml. Samples were compared with 
patients receiving a deceased-donor kidney or SPK transplant 
(total n = 45) who had not received any CNI at the time of sample 
acquisition. Details are shown in Table 1.
CD45RA is a surface marker to distinguish naïve (CD45RA+) 
from activated/memory (CD45RA−) cells, which include cTfh 
cells. Lack of CD45RA is, therefore, often used in gating cTfh cells. 
However, a genetic variant exists, where CD45RO is expressed 
alongside CD45RA, instead of the latter being downregulated 
(28–30), meaning CD45RA cannot be used to distinguish naïve 
from memory cells in those with the genetic variant. Three 
patients in this study had this mutation; therefore, an alternative 
gating strategy for cTfh cells was sought (Figure 1A).
In this cohort of patients, peripheral blood CXCR5+PD-
1+CD4+ cTfh cells (Figure  1A) were significantly reduced in 
both proportion (Figure 1C, p = 0.022) and absolute cell count 
(Figure 1D, p = 0.0042) in tacrolimus treated patients compared 
to untreated patients. Activated CXCR5+PD-1++CD4+ Tfh cells 
(31) (Figure  1B) were also significantly reduced in tacrolimus 
treated patients compared to untreated patients both in propor-
tion (Figure 1E, p = 0.0015) and absolute number (Figure 1F, 
p = 0.0006).
In line with previous studies (7), CXCR5+CD4+ T cells were 
divided into CXCR3+CCR6−CXCR5+CD4+ Tfh1, CXCR3−CCR
6−CXCR5+CD4+ Tfh2, and CXCR3−CCR6+CXCR5+CD4+ Tfh17 
subsets (Figure 1G). There was a global reduction in cTfh cells, 
with all subsets being reduced in tacrolimus treated patients, both 
in proportion (Figure 1H) and absolute count (Figure 1I), sug-
gesting that tacrolimus does not act selectively on cTfh cell sub-
sets. Importantly, the effect of tacrolimus was specific to Tfh cells; 
there was with no difference in either proportion (Figure 1J) or 
absolute count (Figure 1K) of CXCR3+CXCR5−CD45RA−CD4+ 
Th1 cells in tacrolimus treated compared to untreated patients. 
These results indicate a selective effect of tacrolimus on cTfh cells 
compared to other T cell subsets.
FigUre 2 | Tacrolimus treatment does not impact B cell numbers. (a) Gating strategy for peripheral blood B cells. CD38hiCD24− plasmablasts and CD38hiCD24hi 
transitional cells shown as proportion of B cells (B) and absolute cell count (c) comparing deceased donor recipients, receiving no immunosuppression (untreated, 
n = 45) and live donor recipients receiving a week of tacrolimus (tacrolimus-treated, n = 16). CD27+IgD− class-switched memory cells, CD27+IgD+ unswitched 
memory cells, CD27−IgD+ naïve cells and CD27−IgD− cells shown as proportion of B cells (D) and absolute cell count (e) comparing untreated to tacrolimus-treated 
patients. (F) For lymph node B cells, CD38hiBcl6+ germinal center (GC) cells were gated first, then CD38hiCD24− plasmablasts, CD38hiCD24hi transitional cells, 
CD27+IgD− switched memory cells, CD27+IgD+ unswitched memory cells, CD27−IgD+ naïve cells and CD27−IgD− double negative cells as per peripheral blood 
B cells. (g) CD38hiBcl6+ GC B cells in deceased donor recipients, receiving no immunosuppression (untreated, n = 45) and live donor recipients receiving a  
week of tacrolimus (tacrolimus-treated, n = 16). (h) CD38hiCD24hi transitional cells and CD38hiCD24− plasmablasts in untreated and tacrolimus-treated patients.  
(i) CD27+IgD− class-switched memory cells, CD27+IgD+ unswitched memory cells, CD27−IgD+ naïve cells and CD27−IgD− cells in untreated and tacrolimus-treated 
patient. Shown as median and interquartile range, each symbol represents one patient. Analyzed with Mann–Whitney testing, only significant differences are shown 
on graphs.
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Pre-Transplant Tacrolimus Does not 
impact on Peripheral or ln B cell subsets
Because cTfh cells are known to correlate with the frequency 
of circulating plasma cells in the context of vaccination (10), 
we wished to determine if there were any alterations in the 
circulating B cell subsets after CNI treatment. Peripheral blood 
samples were gated as shown in Figure 2A, allowing comparison 
of CD38hiCD24−CD19+ plasmablasts, CD38hiCD24hiCD19+ tran-
sitional cells, CD27+IgD−CD19+ class-switched memory cells, 
CD27+IgD+CD19+ unswitched memory cells, CD27−IgD+CD19+ 
naïve cells, and CD27−IgD−CD19+ cells.
Comparing tacrolimus treated with untreated patients, there 
was no significant difference in CD38hiCD24−CD19+ plasmablasts 
or CD38hiCD24hiCD19+ transitional cells either in proportion 
of CD19+ cells (Figure 2B) or absolute cell count (Figure 2C). 
There was a slight reduction in the proportion of CD19+ cells 
falling into the CD27−IgD− gate (p =  0.03, Figure  2D), but no 
difference in absolute cell count (Figure 2E) and no differences in 
CD27+IgD−CD19+ class-switched memory cells, CD27+IgD+CD19+ 
unswitched memory cells, or CD27−IgD+CD19+ naïve cells.
We then sought to determine whether there were alterations 
in the LN-resident B cell populations. In LN, B cell subsets were 
identified as CD38hiBCL6+CD19+ GC B  cells, non-GC B  cells 
were then divided into the same subsets as peripheral blood 
B cells, consistent with the analyses shown in Figure 2A (gating 
strategy for LN cells shown in Figure  2F). Comparison of LN 
B cells from tacrolimus treated and untreated patients showed no 
significant difference in any B cell subset (Figures 2G–I). These 
data demonstrate that tacrolimus does not alter the frequency of 
B cell subsets in the LN. Of note, there were very few LNs with a 
GC reaction (Figure 2G), which likely reflects the selection of a 
patient cohort without an ongoing immune response in LN. This 
is consistent with our previous work (4), likely because infection 
is a contraindication to proceed with transplantation.
Together, these data show that there were no significant 
differences in absolute B cell numbers in the circulation or the 
proportion of LN B cells between live-donor recipients treated 
with tacrolimus for 1  week (tacrolimus treated patients) com-
pared to deceased donor recipients with no tacrolimus treatment 
(untreated patients).
FigUre 3 | Tacrolimus reduces lymph node (LN) T follicular helper (Tfh) cells. Samples were gated on lymphocytes then live CD4+ cells. LN Tfh were identified as 
(a) CXCR5+PD-1+ with germinal center (GC) Tfh separated out as (B) CXCR5+PD-1++. (c) LN CXCR5+PD-1+ Tfh shown in live donor recipients who had received a 
week of tacrolimus (tacrolimus treated, n = 16) compared to untreated deceased donor recipients (untreated, n = 45). (D) GC CXCR5+PD-1++ Tfh shown in 
tacrolimus treated and untreated. (e) Gating for Bcl6 expression on CD4+ cells. (F) Fluorescence intensity of Bcl6 on CXCR5−PD-1−CD4+ non-Tfh cells, CXCR5−PD-
1+CD4+ Tfh and CXCR5−PD-1++CD4+ GC located Tfh cells. (g) CXCR5+PD-1++Bcl6+ Tfh in untreated compared to tacrolimus treated patients. (h) Pearson 
correlation between CXCR5+PD-1+Bcl6+CD45RA−CD4+ Tfh and CD38+PD-1+Bcl6+CD19+ GC B cells. (i) CXCR3+CXCR5−CD4+ Th1 cells in LNs of untreated and 
tacrolimus treated patients. Shown as median and interquartile range, each symbol represents one patient. Analysed with Mann Whitney testing, only significant 
differences are shown on graphs.
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Pre-Transplant Tacrolimus reduces  
ln cXcr5+PD-1+ Tfh cells
As cTfh cells are considered to be a biomarker of LN Tfh activity 
(8–10, 12–18), we were interested in whether the reductions seen 
in cTfh cells in our patient cohort corresponded to alterations 
in LN Tfh cells. Within the LN, CXCR5+CD4+ T  cells are a 
diverse group of cells, encompassing Tfh cell precursors, which 
have not yet entered the GC; fully differentiated GC-located Tfh; 
and antigen-specific memory Tfh, which express lower levels of 
co-stimulatory markers such as ICOS and PD-1 but are capable 
of rapid recall responses on antigen restimulation (32). To deter-
mine whether tacrolimus treatment had an impact on LN Tfh 
cells similar to cTfh cells, we analyzed multiple subsets of Tfh 
cells within the LN.
Broadly, Tfh cells were identified in the LN as CXCR5+PD-
1+CD4+ cells (Figure 3A) with GC located Tfh identified as the 
CXCR5+PD-1++CD4+ subset (Figure 3B). CXCR5+PD-1+CD4+ 
cells showed a significant reduction (p = 0.037) in tacrolimus 
treated compared to untreated patients (Figure 3C). However, 
CXCR5+PD-1++CD4+ GC Tfh were not significantly different 
(p = 0.15) between tacrolimus treated and untreated patients 
(Figure  3D). Bcl6 expression was highest in CXCR5+PD-
1++CD4+ GC Tfh cells, and intermediate in CXCR5+PD-
1+CD4+ Tfh cells (Figures  3E,F), CXCR5+PD-1++Bcl6+CD4+ 
GC Tfh were not significantly different (p =  0.14) between 
tacrolimus treated and untreated patients (Figure  3G). This 
likely reflects the quiescent nature of the LNs in this patient 
cohort, as there were very few GCs in the LNs of these patients 
(Figure  2G). In support of this, data from an independent 
cohort of inguinal LN samples from our laboratory show 
that there is a significant correlation (r2 = 0.69, p = 0.0004) 
between the number of CXCR5+PD-1++Bcl6+CD4+ GC Tfh 
cells and the number of GC B cells (Figure 3H) in human LN. 
It may also reflect the relatively short duration of tacrolimus 
therapy at the point of analysis, 1  week, suggesting that the 
majority of effects are on Tfh precursors, or memory Tfh with 
FigUre 4 | Tacrolimus does not impact T follicular regulatory (Tfr) or regulatory T cells. Samples were gated on lymphocytes then live CD4+ cells. (a) Regulatory 
T cells (Tregs) were gated as IL-7RloFoxp3+, then (B) Tfr cells were gated as CXCR5+ Tregs. There were no significant differences between Tregs or Tfr in untreated 
deceased donor recipients (untreated) and live donor recipients (tacrolimus treated) in blood either in proportion of cells (c) or absolute cell count (D). There was a 
trend toward lower Tfr in peripheral blood both in proportion of cells (e) and absolute cell count (F), but this did not reach statistical significance on Mann–Whitney 
testing. There were no significant differences in lymph node Tregs (g) or Tfr cells (h) between untreated and tacrolimus treated patients. Shown as median and 
interquartile range, each symbol represents one patient, n = 45 untreated, n = 16 tacrolimus treated. All samples analyzed with Mann–Whitney testing.
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low level PD-1 expression, rather than GC-localized Tfh cells. 
Together, these data suggest that tacrolimus can inhibit human 
Tfh cell differentiation.
As with cTfh cells, LN CXCR5+CD4+ T  cells were divided 
into CXCR3+CCR6−CXCR5+CD4+ Tfh1, CXCR3−CCR6−CXCR
5+CD4+ Tfh2, and CXCR3−CCR6+CXCR5+CD4+ Tfh17 subsets, 
but there were no differences in the proportion of any subset of 
Tfh cells (data not shown). As seen in peripheral blood, there 
were no significant differences in any CXCR5−CD4+ cell subsets, 
including CXCR3+CXCR5−CD4+ Th1 cells, shown as an example 
(Figure 3I).
While GC located Tfh expressing the highest levels of PD-1 
were not diminished by tacrolimus treatment, given the overall 
reduction in both LN Tfh cell precursors and cTfh cells, these 
data support previous work that cTfh cells are a biomarker of 
LN Tfh cells (4, 9, 10, 33, 34) and is important for the clinical 
follow-up of these patients, as only blood samples are available 
after transplantation. Interestingly, unlike GC Tfh, the reduction 
in CXCR5+PD-1++CD4+ in the peripheral blood may suggest 
that cTfh-like cells that resemble GC-Tfh cells are more sensitive 
to calcineurin blockade than GC Tfh. However, this may be due 
to the fact LN that are sampled during surgery contain very few 
GCs, and the cTfh cells reflect the cumulative responses of all 
secondary lymphoid organ GC responses, particularly those 
in the gut that have persistent GC reactions, which were not 
sampled in these patients.
Pre-Transplant Tacrolimus Does  
not impact on Treg or Tfr cells
Given the differences seen in Tfh cells, we sought to determine 
if their regulatory counterparts were altered with tacrolimus 
treatment, as regulatory T  cells (Tregs) can be reduced by 
CNIs (35–38). Tregs were identified as IL-7RloFOXP3+CD4+ 
cells using the gating strategy shown in Figure 4A. Tfr cells 
should express both Treg and Tfh surface markers and were, 
therefore, identified as CXCR5+IL-7RloFOXP3+CD4+ cells 
(Figure 4B).
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There were no significant differences in CD4+ T  cells as a 
whole (data not shown) or in IL-7RloFOXP3+CD4+ Tregs in 
the peripheral blood in either proportion of cells (Figure  4C) 
or absolute count (Figure  4D) in tacrolimus treated patients 
compared to untreated patients. There was a trend toward fewer 
CXCR5+IL-7RloFOXP3+CD4+ Tfr cells in the peripheral blood 
of tacrolimus treated patients both in proportion of CD4+ cells 
(Figure  4E) and absolute cell count (Figure  4F), but this did 
not reach statistical significance. There were no significant dif-
ferences in LN IL-7RloFOXP3+CD4+ Tregs (Figure  4G) or LN 
CXCR5+IL-7RloFOXP3+CD4+ Tfr cells (Figure  4H) between 
tacrolimus treated and untreated patients. These data suggest that 
suppression of Tfr cells, like Tregs, may require higher doses or 
longer duration of CNI treatment than required for suppression 
of Tfh cells (35–38).
Tacrolimus Treatment reduces Tfh cell 
activation, Plasmablast Differentiation, 
and antibody Production In Vitro
To determine if tacrolimus acts directly on Tfh cell activation and 
helper capacity, we used a previously described (7, 34) in vitro 
system to test Tfh cell function, which allows assessment of B 
helper capacity. Peripheral blood CD19+CD27+ memory B cells 
were co-cultured for 11 days with CXCR5+CXCR3+CD4+ Tfh1, 
CXCR5+CXCR3−CD4+ Tfh2/17 or, as a negative control, CXC
R5−CXCR3+/−CD4+ Teffectors. The culture medium contained 
no drug, vehicle control (DMSO), or tacrolimus; therefore, 
all therapy was present throughout the 11-day culture. Flow 
cytometry at the end of culture allowed assessment of B  cell 
alterations with expression of CD38 and loss of CD20 used as 
a marker of plasmablast differentiation (Figure 5A) and of CD4 
T cell alterations with expression of PD-1 as an activation marker 
(Figure 5B). Co-culture of CD19+CD27+ memory B cells with 
Tfh1 and Tfh2/17 led to CD20−CD38hiCD19+ plasmablast dif-
ferentiation in untreated and vehicle treated control co-cultures 
(Figure 5C), while tacrolimus treatment significantly impaired 
plasmablast formation. This lack of plasmablast differentia-
tion was reflected in the absence of IgG (Figure 5D) and IgM 
(Figure 5E) production in the supernatant of tacrolimus treated 
co-cultures compared to untreated and vehicle control. We could 
not perform this analysis on B cells alone, as B cells cultured with 
SEB in the absence of T cells did not survive in culture irrespec-
tive of drug treatment.
The phenotype of cTfh cells altered following co-culture. In 
untreated and vehicle-control treated co-cultures, PD-1 expres-
sion was significantly upregulated (Figure  5F), consistent with 
the cTfh cells becoming activated during co-culture. However, 
this activation was abrogated by tacrolimus treatment, with PD-1 
expression on Teffectors, Tfh1, and Tfh2/17 not significantly dif-
ferent compared to pre-culture levels (Figure 5F). This suggests 
a block in T cell activation, which would limit interaction with 
B cells, thus preventing antibody production. Together, these data 
suggest that tacrolimus in co-culture conditions blocks the activa-
tion and proliferation of Tfh cells, which limits the provision of 
help to B cells, and subsequent antibody production; however, we 
cannot exclude a direct effect on B cells.
DiscUssiOn
T follicular helper cells are essential for long-lived humoral 
immunity, making them critical mediators of both health and 
disease. They are essential for protective immunity following 
vaccination, but have detrimental effects where the production 
of antibodies is undesirable, such as autoimmune disease. For this 
reason, treatments that can specifically suppress Tfh cell differ-
entiation and/or function are needed to treat humoral auto- and 
allo-immunity. Here, we describe that the CNI tacrolimus specifi-
cally suppresses human Tfh cell differentiation in vivo and alters 
B cell helper function in vitro. These data suggest that tacrolimus 
may be a therapeutic option for those conditions where clinically 
undesirable antibody responses are generated. Unfortunately, due 
to the confounding effects of induction immunosuppression and 
treatment of all patients posttransplant with tacrolimus as well as 
additional maintenance agents, it is not possible to say whether 
these early reductions in Tfh cells would have an impact on the 
risk of de novo DSA formation posttransplant in this patient 
cohort.
Calcineurin inhibitors have been used in transplantation 
since their discovery in the 1970s. Their mechanism has been 
well described (39), as calcineurin is a key phosphatase in 
TCR signaling. When the TCR engages with peptide–MHC 
complex, an intracellular calcium flux leads to the activation of 
calcineurin, leading to the de-phosphorylation of NFAT, which 
then translocates to the nucleus and promotes transcription of 
pro-inflammatory cytokines and costimulatory molecules. By 
binding to immunophilins, CNIs form complexes blocking the 
activation of calcineurin and hence downstream NFAT-dependent 
transcription. While B cells can also signal through calcineurin, 
they are less dependent on this pathway to mediate downstream 
effects of BCR engagement than T cells (40, 41). The key effect of 
this blockade is the reduction in IL-2, a cytokine that increases 
T  cell activation and proliferation, recent animal models have 
suggested that Tfh cells are more dependent on NFAT signaling 
than other CD4 T  cell subsets (5). This is consistent with our 
observation that cTfh cells, but not peripheral blood Th1 cells, 
are reduced after tacrolimus treatment. This is likely because 
NFAT is expressed at higher levels in Tfh cells than in other CD4 
subsets (42) and calcium flux in response to TCR engagement has 
been shown in animal models to be higher in Tfh than Th1 cells 
(43) with blockade of NFAT signaling via ciclosporin abrogating 
IL-21 production. Martinez et  al. showed that in NFAT1- and 
NFAT2-deficient mice, both Tfh and GC B  cells were reduced 
and antibody responses to viral infection were impaired (5). This 
was associated with reduced expression of ICOS, PD-1, CD40L, 
and SLAM, key molecules associated with Tfh differentiation and 
function (1). The differentiation of other CD4 T cell subsets was 
not impaired by CD4-specific loss of NFAT, supporting the data 
we have seen in transplant recipients. These data suggest that Tfh 
cells are more dependent on NFAT signaling than other CD4 
subsets, both for activation via ICOS and CD40L interaction, as 
well as downstream effector mechanisms via IL-21 production.
In support of a similar role for NFAT in humans, almost half 
of genes differentially upregulated in Tfh cells are associated with 
NFAT1-binding sites (5). Our data support these findings, with 
FigUre 5 | Tacrolimus reduces plasmablast formation and antibody production in B cell/Tfh co-cultures. (a) Gating strategy for CD19+ cells. (B) Gating strategy for 
CXCR3+/−CD4+ cells. (c) CD20−CD38++ differentiation in CD27+ memory B cells cultured with CXCR5−CD4+ Teffectors, CXCR3+CXCR5+CD4+ Tfh1, or 
CXCR3−CXCR5+CD4+ Tfh2/17, showing tacrolimus treated co-cultures compared to untreated or DMSO control. IgG (D) and IgM (e) production in tacrolimus 
treated co-cultures compared to untreated or DMSO control. (F) Upregulation of PD-1 on CXCR5−CD4+ Teffectors, CXCR3+CXCR5+CD4+ Tfh1, or 
CXCR3−CXCR5+CD4+ Tfh2/17 in untreated, DMSO control, or tacrolimus treated co-cultures, compared to pre-culture expression. For all samples, the height of the 
bar represents the mean of two technical replicates from four biological replicates, the error bar shows SD. All samples analyzed with one-way ANOVA comparing 
treated to untreated followed by Bonferroni multiple comparison test, except F where all post-culture conditions were compared to pre-culture PD-1 expression 
using Dunnett’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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calcineurin blockade by tacrolimus leading to a selective reduc-
tion in Tfh cells when compared to Tregs and Th1 cells. However, 
we did not observe defects in GC B cell frequency in our patients, 
likely because the LN assessed in our study contained very few 
GC B cells, indicative of lack of antigen stimulation. This is not 
surprising as active infection at the time of admission is a con-
traindication to transplantation. Correspondingly, we observed 
very low numbers of CXCR5+PD-1++ GC Tfh in the LN, reflecting 
the non-reactive nature of these LNs in patients without active 
GC reactions.
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Despite the low numbers of GC Tfh cells, we saw a significant 
reduction in the frequency of LN Tfh cells in tacrolimus-treated 
patients. These data support the observation from animal mod-
els that Tfh cells are more dependent on NFAT signaling, and 
hence, more sensitive to CNIs, than other CD4 T  cell subsets. 
This has implications for transplantation, as effective calcineurin 
blockade may have a greater impact on formation of de novo DSA 
than previously thought. Previous studies have shown a global 
reduction in Tfh with tacrolimus treatment (44), although this 
was not significantly different to the reduction seen with other 
immunosuppressive agents, in particular, belatacept, a CTLA-4 Ig 
fusion protein that blocks costimulation and hence limits T cell 
activation (44, 45). Interestingly, de Graav et al. also found that 
tacrolimus blocked in vitro plasmablast differentiation, in keep-
ing with our data (44).
It is well known from epidemiological studies that inadequate 
levels of CNI, whether from non-concordance (46–49) or 
underdosing (50, 51), are associated with increased risk of de 
novo DSA formation, especially after graft failure, where with-
drawal of immunosuppression is strongly associated with DSA 
formation (52, 53). This emphasizes the need for biomarkers to 
identify those patients most at risk of de novo DSA formation 
and allow selective adjustment of immunosuppression. Our 
data provide a possible explanation for the importance of CNIs 
and supports the suggestion (23) that cTfh cells could be used 
as a more selective biomarker to differentiate which patients are 
adequately immunosuppressed and, therefore, at lower risk of 
developing de novo DSA, rather than using trough drug levels, 
which may over- or under-estimate the immunosuppression of 
an individual patient.
In summary, the CNI tacrolimus appears have a greater impact 
on Tfh cells than other CD4+ T cell subsets making it of therapeutic 
interest in both transplantation and autoimmune disease, where 
increased cTfh cell frequency and an active GC reaction have 
been associated with autoantibody levels and end organ damage.
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